Herbert Irving Comprehensive Cancer Center
Investigator
Catherine Shu, MD
Email
cas2145@cumc.columbia.edu

Dr. Catherine Shu is a board-certified medical oncologist specializing in the treatment of thoracic cancers, especially lung cancer. She received her undergraduate degree from Princeton University, followed by her M.D. from Columbia University College of Physicians and Surgeons. After residency at Columbia University Medical Center, Dr. Shu completed her fellowship at Memorial Sloan Kettering Cancer Center, where she was appointed Chief Fellow.

She has presented her work at numerous national conferences and was awarded an American Society for Clinical Oncology (ASCO) Merit Award for her research. She is particularly interested in immunotherapy and its potential combinations with chemotherapeutics and targeted therapies, as well as novel agents.

Of all her achievements, she is proudest to be able to offer individualized and compassionate care to each and every one of her patients. She understands that each patient and family carries forth a different set of beliefs, goals, and needs. Working alongside an exceptional multidisciplinary team, she is dedicated to improving the survival and bettering the quality of life of her patients.


Clinical Studies Managed By This Investigator:
Condition Study Title
Cancer [ CLOSED ] A study for patients with advanced cancers using study drug JNJ-61610588
Lung Cancer [ CLOSED ] A study for patients with non-small cell lung cancer (NSCLC) using study drug atezolizumab with standard chemotherapy to shrink tumors
Solid Tumors [ CLOSED ] A study for patients with locally advanced or metastatic solid tumors using study drug demcizumab
Lung Cancer [ CLOSED ] A study for patients with advanced Non small cell lung cancer using study drug Nivolumab
Lung Cancer [ CLOSED ] A study for patients with small cell lung cancer using study drug SGI-110
Lung Cancer [ CLOSED ] Study to Evaluate Novel Combination Therapies in Subjects with Previously Treated EGFRm NSCLC
Lung Cancer [ CLOSED ] Study of Drug in Combination with Traditional Chemotherapy for Patients with Stage IV Small-Cell Lung Cancer (SCLC)
Lung Cancer [ CLOSED ] HUDSON: Study of Multiple Treatments in Patients with Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer Study of Study Drug JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer
Lung Cancer [ CLOSED ] A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
Lung Cancer Study of Therapies in Participants with Resectable (removable) and Untreated Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer Study of JNJ-93841937 Participants with Advanced Non-Small Cell Lung Cancer
Lung Cancer [ CLOSED ] Study of Durvalumab + Tremelimumab in Non-Small Cell Lung Cancer Patients After Adjuvant Treatment
Lung Cancer Study of Amivantamab and Carboplatin-Pemetrexed Therapy, versus Carboplatin-Pemetrexed, in Participants With Non-Small Cell Lung Cancer
Lung Cancer Study of Durvalumab with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)
Lung Cancer Study of Combining Osimertinib with and without Ramucirumab in Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer Study of Osimertinib (TAGRISSOTM) in Non-Small Cell Lung Cancer (NeoADAURA) Patients
Lung Cancer Study of Atezolizumab and Tiragolumab Alone or in Combination with Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer Study in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) whose Disease has Gotten Worse After Osermitinib Treatment
Lung Cancer Study of Capmatinib for Patients with Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer Study of Pembrolizumab Alone or in Combination with Chemotherapy in Older Patients with Non-Small Cell Lung Cancer